Maekawa M - Search Results

1

Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.

Matsui H, Takeshita A, Naito K, Shinjo K, Shigeno K, Maekawa M, Yamakawa Y, Tanimoto M, Kobayashi M, Ohnishi K, Ohno R. Matsui H, et al. Among authors: maekawa m. Leukemia. 2002 May;16(5):813-9. doi: 10.1038/sj.leu.2402459. Leukemia. 2002. PMID: 11986941

2

Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.

Takeshita A, Shinjo K, Naito K, Matsui H, Sahara N, Shigeno K, Horii T, Shirai N, Maekawa M, Ohnishi K, Naoe T, Ohno R. Takeshita A, et al. Among authors: maekawa m. Leukemia. 2005 Aug;19(8):1306-11. doi: 10.1038/sj.leu.2403807. Leukemia. 2005. PMID: 15920495

3

CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.

Takeshita A, Yamakage N, Shinjo K, Ono T, Hirano I, Nakamura S, Shigeno K, Tobita T, Maekawa M, Kiyoi H, Naoe T, Ohnishi K, Sugimoto Y, Ohno R. Takeshita A, et al. Among authors: maekawa m. Leukemia. 2009 Jul;23(7):1329-36. doi: 10.1038/leu.2009.77. Epub 2009 Apr 16. Leukemia. 2009. PMID: 19369961

4

P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As(2)O(3)), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cells.

Takeshita A, Shinjo K, Naito K, Matsui H, Shigeno K, Nakamura S, Horii T, Maekawa M, Kitamura K, Naoe T, Ohnishi K, Ohno R. Takeshita A, et al. Among authors: maekawa m. Leukemia. 2003 Mar;17(3):648-50. doi: 10.1038/sj.leu.2402851. Leukemia. 2003. PMID: 12646961 No abstract available.

5

Impairment of heart rate variability control during arsenic trioxide treatment for acute promyelocytic leukemia.

Takeshita A, Uehara A, Shinjo K, Naito K, Sahara N, Yamazaki K, Katoh H, Kamikawa T, Ohnishi K, Maekawa M, Hayashi H, Ohno R. Takeshita A, et al. Among authors: maekawa m. Leukemia. 2004 Mar;18(3):647-8. doi: 10.1038/sj.leu.2403248. Leukemia. 2004. PMID: 14671633 No abstract available.

6

Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum.

Kotani K, Maekawa M, Kanno T, Kondo A, Toda N, Manabe M. Kotani K, et al. Among authors: maekawa m. Biochim Biophys Acta. 1994 Nov 17;1215(1-2):121-5. doi: 10.1016/0005-2760(94)90100-7. Biochim Biophys Acta. 1994. PMID: 7947993

7

[Lactate dehydrogenase (LD)].

Maekawa M. Maekawa M. Rinsho Byori. 2001 Nov;Suppl 116:81-9. Rinsho Byori. 2001. PMID: 11797384 Review. Japanese.

8

Comparison of a new system (Compactdry SCD) with conventional methods for quantitative urine cultures.

Horii T, Morita M, Kameno Y, Kanno T, Maekawa M. Horii T, et al. Among authors: maekawa m. Lett Appl Microbiol. 2002;35(6):499-503. doi: 10.1046/j.1472-765x.2002.01236.x. Lett Appl Microbiol. 2002. PMID: 12460432

9

Hypertriglyceridemia characterized by low-density lipoprotein phenotype and lipoprotein lipase gene mutation.

Li J, Kondo A, Maekawa M, Kanamori M, Kanno T. Li J, et al. Among authors: maekawa m. Clin Chem Lab Med. 2000 Dec;38(12):1263-70. doi: 10.1515/CCLM.2000.199. Clin Chem Lab Med. 2000. PMID: 11205691

10

[Lactic dehydrogenase M subunit (muscle type) deficiency].

Maekawa M, Sudo K, Kanno T. Maekawa M, et al. Ryoikibetsu Shokogun Shirizu. 2001;(36):43-6. Ryoikibetsu Shokogun Shirizu. 2001. PMID: 11596429 Review. Japanese. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,117 results

Search Page